Pioglitazone takes a proactive stance in type 2 diabetes

Author：

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1507, 2005-01, pp. : 11-12

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Safety and Tolerability of Pioglitazone in High-Risk Patients with Type 2 Diabetes: An Overview of Data from PROactive

By Dormandy John

Drug Safety, Vol. 32, Iss. 3, 2009-01 ,pp. : 187-202

Adis International

Access to resources Recommend Favorite

Spotlight on pioglitazone in type 2 diabetes

Inpharma, Vol. 1, Iss. 1268, 2000-01 ,pp. : 11-12

Adis International

Access to resources Recommend Favorite

Pioglitazone pays dividends in type 2 diabetes mellitus

Inpharma, Vol. 1, Iss. 1612, 2007-01 ,pp. : 3-4

Adis International

Access to resources Recommend Favorite

Review of approved pioglitazone combinations for type 2 diabetes

By Forst Thomas Hanefeld Markolf Pfüützner Andreas

Expert Opinion on Pharmacotherapy, Vol. 12, Iss. 10, 2011-07 ,pp. : 1571-1584

Informa Healthcare

Access to resources Recommend Favorite

Pioglitazone improves lipid profiles in type 2 diabetes

Inpharma, Vol. 1, Iss. 1243, 2000-01 ,pp. : 16-16

Adis International

Access to resources Recommend Favorite